Asset Details
Do you wish to reserve the book?
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Do you wish to request the book?
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
2020
Overview
Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic
E coli
Nissle as a versatile platform for the development of a living biotherapeutic for the treatment of cancer. The engineered bacterial strain, referred to as SYNB1891, targets STING-activation to phagocytic antigen-presenting cells (APCs) in the tumor and activates complementary innate immune pathways. SYNB1891 treatment results in efficacious antitumor immunity with the formation of immunological memory in murine tumor models and robust activation of human APCs. SYNB1891 is designed to meet manufacturability and regulatory requirements with built in biocontainment features which do not compromise its efficacy. This work provides a roadmap for the development of future therapeutics and demonstrates the transformative potential of synthetic biology for the treatment of human disease when drug development criteria are incorporated into the design process for a living medicine.
Synthetic biology can be used to create rationally designed living therapeutics. Here the authors engineer
E. coli
Nissle to target STING activation in antigen presenting cells for the treatment of solid tumors and demonstrate preclinical activity in murine models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/21
/ 14/35
/ 38
/ 38/22
/ 38/23
/ 38/5
/ 45/90
/ 64
/ Animals
/ Antigen-Presenting Cells - immunology
/ Antigen-Presenting Cells - metabolism
/ Antigens
/ Biology
/ E coli
/ Escherichia coli - immunology
/ Escherichia coli - metabolism
/ Genetic Engineering - methods
/ Humanities and Social Sciences
/ Humans
/ Immunity
/ Interferon Type I - immunology
/ Interferon Type I - metabolism
/ Membrane Proteins - genetics
/ Membrane Proteins - immunology
/ Membrane Proteins - metabolism
/ Mice
/ Science
/ Signal Transduction - genetics
/ Signal Transduction - immunology
/ Tumors
